Newly developed retatrutide, a combined-action drug targeting both GLP-1 and GIP receptors, is generating considerable buzz within the healthcare community. Initial clinical trials have shown substantial decreases in body size and advancements in physiological markers for patients with overweight. Researchers believe this ground-breaking approa… Read More